Nausea and vomiting induced by pharmacotherapy: have all issues of maintenance therapy been resolved?

Many patients with various localizations of malignant neoplasms require therapy aimed at preventing or reducing the manifestations nausea and vomiting induced by anticancer pharmacotherapy. New drugs to prevent development complications chemotherapy are critical improve quality life their adherence therapy. Palonosetron, a new generation 5-HT3 receptor antagonist, has long half-life (up 40 hours) 30-fold higher affinity for receptors compared previous generations antagonists. Clinical studies have shown ability palonosetron in combination dexamethasone and, if indicated, neurokinin antagonists effectively during single- multi-day cycles both solid tumors hematological diseases, including high-dose chemotherapy, preparation transplantation auto- allogeneic stem cells. The innovative oral drug Akynzeo is currently available use clinical practice, which includes 2 highly selective NK1 fixed doses. prevents moderate emetogenic more than 90 % cases, acute delayed phases.